| 000 | 02671nam a22004095i 4500 | ||
|---|---|---|---|
| 003 | ESmaUEC | ||
| 006 | a||||fo|||| 00| 0 | ||
| 007 | cr nn nnnaamaa | ||
| 040 |
_aES-MaUEC _bspa _cES-MaUEC |
||
| 336 |
_aTexto _btxt _2rdacontent |
||
| 710 | 2 |
_aSpringerLink (Online service) _0http://id.loc.gov/authorities/names/no2005046756 _1http://viaf.org/viaf/148105729 _9106996 |
|
| 999 |
_c100831 _d100831 _x1 |
||
| 001 | 100831 | ||
| 005 | 20230102113013.0 | ||
| 008 | 180424s2018 gw | s |||| 0|eng d | ||
| 020 | _a9783319782386 | ||
| 024 | 7 |
_a10.1007/978-3-319-78238-6 _2doi |
|
| 050 | 4 |
_aRC261 _b2018 EB |
|
| 245 | 1 | 0 |
_aResistance to Ibritumomab in Lymphoma _cedited by Makoto Hosono, Jean-François Chatal. |
| 264 | 1 |
_aCham, Switzerland _bSpringer International Publishing _c2018 |
|
| 300 | _a1 recurso en línea (XIII, 158 páginas 18 ilustraciones,14 ilustraciones a color) | ||
| 337 |
_2rdamedia _aelectrónico _bc |
||
| 338 |
_2rdacarrier _arecurso electrónico _bcr |
||
| 347 |
_atext file _bPDF |
||
| 490 | 0 |
_aResistance to Targeted Anti-Cancer Therapeutics _x2196-5501 _v18 |
|
| 490 | 0 | _aBiomedical and Life Sciences (Springer-11642) | |
| 505 | 0 | _aClinical Use and Efficacy of Ibritumomab in B-cell Lymphoma -- Biology and Pathology of B-cell lymphoma -- Resistance to Y-90 Ibritumomab Tiuxetan Therapy -- Features of Ibritumomab as Radionuclide Therapy -- Radiological Evaluation of Response and Resistance of Ibritumomab -- Characteristics of Ibritumomab as Radionuclide Therapy Agent -- Resistance and Heterogeneity of Intratumoral Antibody Distribution -- Radiation Dosimetry in Ibritumomab Therapy -- Combining RAIT and immune-based therapies to overcome resistance in cancer? -- Prospects for enhancing efficacy of radioimmunotherapy -- Index. | |
| 520 | 3 | _aThis volume, in discussing resistance to ibritumomab, will focus on the mechanism, hematological aspects, radiological and nuclear medicine aspects, and medical physics that deal with radiation dosimetry, and will outline future prospects for overcoming resistance and enhancing efficacy of ibritumomab. | |
| 988 | _aEBSPRINGER_2018 | ||
| 650 | 7 |
_9139308 _aCáncer _2embne |
|
| 700 | 1 |
_aHosono, Makoto. _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt |
|
| 700 | 1 |
_aChatal, Jean-François. _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt |
|
| 776 | 0 | 8 |
_iEdición impresa: _z9783319782379 |
| 776 | 0 | 8 |
_iEdición impresa: _z9783319782393 |
| 856 | 4 | 0 |
_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-319-78238-6 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid) |
| 942 |
_2lcc _cLE |
||
| 998 |
_b06/2019 _dz _eIG _zSI |
||